Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × Loratadine × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphangioleiomyomatosis 1

Interventions

Cisplatin 247 Carboplatin 177 Oxaliplatin 168 Capecitabine 167 Docetaxel 161 apatinib 155 Paclitaxel 147 Bevacizumab 143 Gemcitabine 139 Radiotherapy 138 camrelizumab 130 Fluorouracil 129 Cyclophosphamide 118 Irinotecan 112 Drug Therapy 94 sintilimab 92 Etoposide 92 S 1 (combination) 79 anlotinib 74 Leucovorin 74 Doxorubicin 72 pembrolizumab 70 tislelizumab 68 toripalimab 67 Pemetrexed 67 Dexamethasone 63 Rituximab 62 Neoadjuvant Therapy 60 Cetuximab 60 Trastuzumab 57

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05190627 2022-01-27

LORALAM

Institut d'Investigació Biomèdica de Bellvitge

Phase 2 Unknown

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡